A phase I study of raltitrexed and paclitaxel given every 3 weeks to patients with solid tumors

Cancer

Volumn 86, Issue 3, 1999, Pages 528-532

  Vokes, Everett E ^a,b   Goh, Boon C ^a   Bertucci, Donna ^a   Vogelzang, Nicholas J ^a,b   Mani, Sridhar ^a   Ratain, Mark J ^a,b  

^a UNIVERSITY OF CHICAGO   (United States)

^b Cancer Center   (United States)

Author keywords

Combination; Paclitaxel; Phase I; Raltitrexed

Indexed keywords

PACLITAXEL; RALTITREXED; THYMIDYLATE SYNTHASE INHIBITOR;

ADULT; AGED; ALOPECIA; ANTINEOPLASTIC ACTIVITY; ARTHRALGIA; ARTICLE; BLOOD TOXICITY; CANCER COMBINATION CHEMOTHERAPY; CANCER REGRESSION; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE CALCULATION; DRUG EFFICACY; DRUG INDICATION; DRUG MECHANISM; DRUG TOLERABILITY; FEMALE; GASTROINTESTINAL SYMPTOM; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; MALE; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; SOLID TUMOR; THROMBOCYTE TRANSFUSION; TREATMENT OUTCOME;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; COHORT STUDIES; DRUG ADMINISTRATION SCHEDULE; DRUG EVALUATION; FEMALE; HUMANS; LYMPHOMA; MALE; MIDDLE AGED; NEOPLASMS; NEUTROPENIA; PACLITAXEL; QUINAZOLINES; THIOPHENES;

EID: 0033178968     PISSN: 0008543X     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1097-0142(19990801)86:3<528::AID-CNCR23>3.0.CO;2-R     Document Type: Article

References (20)

1. Rowinsky EK, Donehower RC. Drug therapy: paclitaxel (Taxol). N Engl J Med 1996;332:1004-14.
2. Bonomi P, Kim K, Kusler J, Johnson D. Cisplatin/etoposide vs paclitaxel/cisplatin/G-CSF vs paclitaxel/cisplatin in non-small cell lung cancer. Oncology (Huntingt) 1997;11(4 Suppl 3):9-10.
3. Belani CP, Natale RB, Lee JS, Socinski M, Robert F, Waterhouse D, et al. Randomized phase III trial comparing cisplatin/etoposide versus carboplatin/paclitaxel in advanced and metastatic non-small cell lung cancer (NSCLC). Proc Am Soc Clin Oncol 1998;17:1751.
4. Langer CJ, Leighton JC, Comis RL, O'Dwyer PJ, McAleer CA, Bonjo CA, et al. Paclitaxel and carboplatin in combination in the treatment of advanced non-small cell lung cancer: a phase II toxicity response and survival analysis. J Clin Oncol 1995;13:1860-70.
5. Seidman AD. The emerging role of paclitaxel in breast cancer therapy. Clin Cancer Res 1995;1:247.
6. Gianni L, Munzone E, Capri G, Fulfaro F, Tarenzi E, Villani F, et al. Paclitaxel by 3-hour infusion in combination with bolus doxorubicin in women with untreated metastatic breast cancer. J Clin Oncol 1995;13:2688-99.
7. Holmes F. Combination chemotherapy with Taxol (paclitaxel) in metastatic breast cancer. Ann Oncol 1994;5(Suppl 6):S23-7.
8. Cunningham D, Zalcberg J, Smith I, Gore M, Pazdur R, Burris H III, et al. "Tomudex" (ZD1694): a novel thymidylate synthase inhibitor with clinical antitumor activity in a range of solid tumors. Ann Oncol 1996;7:179-82.
9. Zalcberg JR, Cunningham D, Cutsem EV, Francois E, Schornagel I, Adenis A, et al. ZD1694: a novel thymidylate synthase inhibitor with substantial activity in the treatment of patients with advanced colorectal cancer. J Clin Oncol 1996; 14:716-21.
10. Jackman AL, Farrugia DC, Gibson W, Kimbell R, Harrap KR, Stephen TC, et al. ZD1694 (Tomudex): a new thymidylate synthase inhibitor with activity in colorectal cancer. Eur J Cancer 1995:31A:1277-82.
11. Jackman AL, Taylor GA, Gibson W, Kimbell R, Brown M, Calvert AH, et al. ICI D1694, a quinozoline antifolate thymidylate synthase inhibitor that is a potent inhibitor of L1210 tumor cell growth in vitro and in vivo: a new agent for clinical study. Cancer Res 1991;51:5579-86.
12. Ward WHJ, Kimbell R, Jackman AL. Kinetic characteristics of ICI D 1694: a quinozoline antifolate which inhibits thymidylate synthase. Biochem Pharmacol 1992;43:2029-31.
13. Gibson W, Bisset GMF, Marsham PR, Kelland LR, Judson IR, Jackman AL. The measurement of polyglutamate metabolites of the thymidylate synthase inhibitor, ICI D1694, in mouse and human cultured cells. Biochem Pharmacol 1993; 45:863-9.
14. Clark SJ, Hanwell J, de Boer M, Planting A, Verweij J, Walker M, et al. Phase I trial of ZD1694, a new folate-based thymidylate synthase inhibitor, in patients with solid tumors. J Clin Oncol 1996;14:1495-503.
15. Cunningham D. Mature results from three large controlled studies with raltitrexed ("Tomudex"). Br J Cancer 1998; 77(Suppl 2):15-21.
16. Cunningham D, Zalcberg JR, Rath U, Oliver I, Van Cutsem E, Svensson C, et al. Final results of a randomized trial comparing 'Tomudex' (raltitrexed) with 5-fluorouracil plus leucovorin in advanced colorectal cancer. Ann Oncol 1996;7:961-5.
17. Cocconi G, Cunningham D, Van Cutsem E, Francois E, Gustavsson B, van Hazel G, et al. Open, randomized, multicenter trial of raltitrexed versus fluorouracil plus high-dose leucovorin in patients with advanced colorectal cancer. J Clin Oncol 1998;16:2943-52.
18. Pazdur R, Vincent M. Raltitrexed (Tomudex) vs 5-fluorouracil + leucovorin (5-FU + LV) in pts with advanced colorectal cancer (ACC): results of a randomized multicenter North American trial [abstract]. Proc Am Soc Clin Oncol 1997;16: 801a.
19. Fizazi K, Soria JC, Bonnay M, Ruffie P, Ducreux M, Le Chevalier T, et al. Phase I/II dose-finding and pharmacokinetic (PK) study of 'Tomudex' (T) in combination with oxaliplatin (O) in advanced solid tumors. Proc Am Soc Clin Oncol 1998;17:773.
20. Harstrick A, Mayer S, Muller C, Hilger R, Dohmen D, Kreisel C, et al. Combination therapy with infusional 5-FU and 'Tomudex' for patients (pts) with advanced colorectal cancer-a phase I study. Proc Am Soc Clin Oncol 1998;17:772.